BCM
AZN icon

BlueCrest Capital Management’s AstraZeneca AZN Stock Holding History

BlueCrest Capital Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-4,178
Closed -$317K – 1171
2018
Q4 		$317K Buy
+4,178
New +$326K 0.02% 489
2017
Q1 		– Sell
-26,777
Closed -$1.46M – 741
2016
Q4 		$1.46M Buy
+26,777
New +$1.52M 0.08% 306

Other funds holding AZN

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlueCrest Capital Management's AZN Position: Q1 2019 in Review

BlueCrest Capital Management sold out of AstraZeneca (AZN) in Q1 2019, closing a stake of 4,178 shares — an estimated $317K sold.

BlueCrest Capital Management first reported a position in AZN in Q4 2016 and held it in 2 quarters. The position peaked at $1.46M in Q4 2016. 561 funds tracked by Wall St. Rank hold AZN as of Q1 2019.

  • BlueCrest Capital Management reported no remaining AstraZeneca position as of Q1 2019 after selling out during the quarter.
  • BlueCrest Capital Management sold 4,178 AstraZeneca shares in Q1 2019, an estimated $317K.
  • BlueCrest Capital Management first reported a position in AstraZeneca in Q4 2016 and held it in 2 quarters.
  • BlueCrest Capital Management's AstraZeneca position peaked at $1.46M in Q4 2016.
  • 561 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2019.

Based on BlueCrest Capital Management's 13F filing for Q1 2019, filed 15 May 2019.